Old Web
English
Sign In
Acemap
>
authorDetail
>
J. San Martin
J. San Martin
Eli Lilly and Company
Medicine
Osteoporosis
Internal medicine
Discontinuation
Bone mineral
4
Papers
459
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (4)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
A PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY INVESTIGATING THE EFFICACY AND SAFETY OF BUROSUMAB, AN ANTI-FGF23 ANTIBODY, IN ADULT X-LINKED HYPOPHOSPHATEMIA (XLH)
2018
Osteoporosis International
Peter Kamenicky
Robin H. Lachmann
Thomas O. Carpenter
Michel Cohen-Solal
R Eastell
M. L. Brandi
R K Crowley
Stuart H. Ralston
M K Javaid
R W Keen
Karine Briot
Hae Il Cheong
Yasuo Imanishi
Nobuaki Ito
Hiroyuki Tanaka
Lin Zhang
Christina Theodore-Oklota
Matt Mealiffe
J. San Martin
Karl L. Insogna
Show All
Source
Cite
Save
Citations (1)
Effect of raloxifene after recombinant teriparatide [hPTH(1–34)] treatment in postmenopausal women with osteoporosis
2008
Osteoporosis International
S. Adami
J. San Martin
Manuel Muñoz-Torres
Michael J. Econs
L. Xie
Gail P. Dalsky
M. McClung
Dieter Felsenberg
John Brown
M. L. Brandi
A. Sipos
Show All
Source
Cite
Save
Citations (59)
Severity of vertebral fracture reflects deterioration of bone microarchitecture
2007
Osteoporosis International
Harry K. Genant
Pierre D. Delmas
Peiqi Chen
Y. Jiang
Erik F. Eriksen
Gail P. Dalsky
Robert Marcus
J. San Martin
Show All
Source
Cite
Save
Citations (137)
Teriparatide effects on vertebral fractures and bone mineral density in men with osteoporosis: treatment and discontinuation of therapy.
2005
Osteoporosis International
Jean-Marc Kaufman
Eric S. Orwoll
Stefan Goemaere
J. San Martin
A Hossain
Gp Dalsky
Robert Lindsay
Bh Mitlak
Show All
Source
Cite
Save
Citations (262)
1